These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 9174600

  • 1. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
    Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ.
    Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
    [Abstract] [Full Text] [Related]

  • 2. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.
    Peiper M, Goedegebuure PS, Izbicki JR, Eberlein TJ.
    Anticancer Res; 1999 May; 19(4A):2471-5. PubMed ID: 10470176
    [Abstract] [Full Text] [Related]

  • 3. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W.
    Cancer Res; 1998 Feb 15; 58(4):732-6. PubMed ID: 9485028
    [Abstract] [Full Text] [Related]

  • 4. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
    Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ.
    J Immunol; 1995 Nov 01; 155(9):4486-91. PubMed ID: 7594611
    [Abstract] [Full Text] [Related]

  • 5. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
    Peiper M, Goedegebuure PS, Alldinger I, Knoefel WT, Izbicki JR, Eberlein TJ.
    Anticancer Res; 2002 Nov 01; 22(6A):3357-63. PubMed ID: 12530087
    [Abstract] [Full Text] [Related]

  • 6. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
    Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ.
    Cancer Res; 1994 Jul 01; 54(13):3387-90. PubMed ID: 7912166
    [Abstract] [Full Text] [Related]

  • 7. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
    Peoples GE, Yoshino I, Douville CC, Andrews JV, Goedegebuure PS, Eberlein TJ.
    J Immunol; 1994 May 15; 152(10):4993-9. PubMed ID: 7909829
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE.
    Cancer; 2006 Jun 01; 106(11):2309-17. PubMed ID: 16596621
    [Abstract] [Full Text] [Related]

  • 9. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
    Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ.
    J Immunol; 1994 Mar 01; 152(5):2393-400. PubMed ID: 8133050
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
    Goedegebuure PS, Douville CC, Doherty JM, Linehan DC, Lee KY, Ganguly EK, Eberlein TJ.
    Cell Immunol; 1997 Feb 01; 175(2):150-6. PubMed ID: 9023420
    [Abstract] [Full Text] [Related]

  • 11. Shared T cell epitopes in epithelial tumors.
    Peoples GE, Smith RC, Linehan DC, Yoshino I, Goedegebuure PS, Eberlein TJ.
    Cell Immunol; 1995 Sep 01; 164(2):279-86. PubMed ID: 7656335
    [Abstract] [Full Text] [Related]

  • 12. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.
    Clin Cancer Res; 2008 Oct 15; 14(20):6487-95. PubMed ID: 18927288
    [Abstract] [Full Text] [Related]

  • 13. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
    Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ.
    J Immunol; 1993 Nov 15; 151(10):5481-91. PubMed ID: 8228240
    [Abstract] [Full Text] [Related]

  • 14. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
    Zaks TZ, Rosenberg SA.
    Cancer Res; 1998 Nov 01; 58(21):4902-8. PubMed ID: 9809997
    [Abstract] [Full Text] [Related]

  • 15. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E.
    J Immunol; 1995 Mar 01; 154(5):2257-65. PubMed ID: 7868898
    [Abstract] [Full Text] [Related]

  • 16. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.
    Crowley NJ, Darrow TL, Quinn-Allen MA, Seigler HF.
    J Immunol; 1991 Mar 01; 146(5):1692-9. PubMed ID: 1671580
    [Abstract] [Full Text] [Related]

  • 17. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
    Takahashi T, Irie RF, Morton DL, Hoon DS.
    Cell Immunol; 1997 Jun 15; 178(2):162-71. PubMed ID: 9225007
    [Abstract] [Full Text] [Related]

  • 18. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
    Sotiriadou R, Perez SA, Gritzapis AD, Sotiropoulou PA, Echner H, Heinzel S, Mamalaki A, Pawelec G, Voelter W, Baxevanis CN, Papamichail M.
    Br J Cancer; 2001 Nov 16; 85(10):1527-34. PubMed ID: 11720440
    [Abstract] [Full Text] [Related]

  • 19. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
    Takahashi T, Irie RF, Nishinaka Y, Hoon DS.
    Clin Cancer Res; 1997 Aug 16; 3(8):1363-70. PubMed ID: 9815820
    [Abstract] [Full Text] [Related]

  • 20. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.
    Cancer Res; 1997 Feb 15; 57(4):735-41. PubMed ID: 9044853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.